Skip to main content
Erschienen in: Discover Oncology 5-6/2016

04.10.2016 | Review

Development of Metabolic Syndrome Associated to Cancer Therapy: Review

verfasst von: Stephania Casco, Elena Soto-Vega

Erschienen in: Discover Oncology | Ausgabe 5-6/2016

Einloggen, um Zugang zu erhalten

Abstract

Long-term childhood cancer survivors are at great risk of developing late adverse effects after treatment, such as, reduced growth, obesity, decreased fertility, high blood pressure, cardiovascular diseases, impaired glucose, another form of cancer, among others organ dysfunctions, some of them are part of the metabolic syndrome. Metabolic syndrome and cancer connection is still not entirely understood, but there are some notions about it. Metabolic alterations produced during childhood cancer are more likely determined by treatments like radiotherapy, chemotherapy, glucocorticoids therapy, and surgery. Cancer treatment is associated to vascular alterations, hormone deficiencies, changes in insulin sensitivity, lipid metabolism, and inflammatory mediators. Obesity has been considered a crucial component in metabolic syndrome; obesity risk factors during childhood cancer include cranial radiation, female gender, and exposure to glucocorticoids such as dexamethasone. In addition, local radiotherapy or surgery may cause endocrine deficiencies, depends on the directly damage of endocrine organs. Patients who received some types of cancer treatment should be evaluated periodically to early diagnostic metabolic disorders associated to antineoplastic therapy.
Literatur
1.
Zurück zum Zitat Berbis J, Michel G, Baruchel A, Bertrand Y, Chastagner P, Demeocq F, et. al. (2014) Cohort profile: the French childhood cancer survivor study for leukaemia (LEA Cohort). Int J Epidemiol dyu031 Berbis J, Michel G, Baruchel A, Bertrand Y, Chastagner P, Demeocq F, et. al. (2014) Cohort profile: the French childhood cancer survivor study for leukaemia (LEA Cohort). Int J Epidemiol dyu031
2.
Zurück zum Zitat Barnea D, Raghunathan N, Friedman DN, Tonorezos ES (2015) Obesity and metabolic disease after childhood cancer. Oncology 29(11):849PubMed Barnea D, Raghunathan N, Friedman DN, Tonorezos ES (2015) Obesity and metabolic disease after childhood cancer. Oncology 29(11):849PubMed
3.
Zurück zum Zitat Latoch E, Muszyńska-Rosłan K, Panas A, Panasiuk A, Rutkowska-Żelazowska B, Konstantynowicz J, Krawczuk-Rybak M (2015) Bone mineral density, thyroid function, and gonadal status in young adult survivors of childhood cancer. Contemp Oncol 19(2):142–147 Latoch E, Muszyńska-Rosłan K, Panas A, Panasiuk A, Rutkowska-Żelazowska B, Konstantynowicz J, Krawczuk-Rybak M (2015) Bone mineral density, thyroid function, and gonadal status in young adult survivors of childhood cancer. Contemp Oncol 19(2):142–147
4.
Zurück zum Zitat Siviero-Miachon A, Spinola-Castro A, Guerra-Junior G (2008) Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc Health Risk Manag 4(4):825–836PubMedPubMedCentral Siviero-Miachon A, Spinola-Castro A, Guerra-Junior G (2008) Detection of metabolic syndrome features among childhood cancer survivors: a target to prevent disease. Vasc Health Risk Manag 4(4):825–836PubMedPubMedCentral
5.
Zurück zum Zitat Armstrong G, Joshi V, Ness K, Marwick T, Zhang N, Srivastava D, Griffin B et al (2015) Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer results from the St. Jude lifetime cohort study. J Am Coll Cardiol 65(23):2511–2522CrossRefPubMedPubMedCentral Armstrong G, Joshi V, Ness K, Marwick T, Zhang N, Srivastava D, Griffin B et al (2015) Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer results from the St. Jude lifetime cohort study. J Am Coll Cardiol 65(23):2511–2522CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Mitry M, Edwards J (2016) Doxorubicin induced heart failure: phenotype and molecular mechanisms. IJC Heart Vasculature 10:17–24 Mitry M, Edwards J (2016) Doxorubicin induced heart failure: phenotype and molecular mechanisms. IJC Heart Vasculature 10:17–24
7.
Zurück zum Zitat Iughetti L, Bruzzi P, Predieri B, Paolucci P (2012) Obesity in patients with acute lymphoblastic leukemia in childhood. Ital J Pediat 38(1):1 Iughetti L, Bruzzi P, Predieri B, Paolucci P (2012) Obesity in patients with acute lymphoblastic leukemia in childhood. Ital J Pediat 38(1):1
8.
Zurück zum Zitat Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM (2014) Metabolic syndrome and cardiovascular risk among long‐term survivors of acute lymphoblastic leukaemia‐From the St. Jude Lifetime Cohort. B J Haematol 165(3):364--374 Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM (2014) Metabolic syndrome and cardiovascular risk among long‐term survivors of acute lymphoblastic leukaemia‐From the St. Jude Lifetime Cohort. B J Haematol 165(3):364--374
9.
Zurück zum Zitat Bhojwani D, Darbandi R, Pei D, Ramsey L, Chemaitilly W, Sandlund J, Cheng C et al (2014) Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer 50(15):2685–2694CrossRefPubMedPubMedCentral Bhojwani D, Darbandi R, Pei D, Ramsey L, Chemaitilly W, Sandlund J, Cheng C et al (2014) Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. Eur J Cancer 50(15):2685–2694CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Quintanilla-Flores D, Flores-Caballero M, Rodríguez-Gutiérrez R, Tamez-Pérez H, González-González J (2014) Acute pancreatitis and diabetic ketoacidosis following L-Asparaginase/prednisone therapy in acute lymphoblastic leukemia. Case Rep Oncol Med 2014:1–3CrossRef Quintanilla-Flores D, Flores-Caballero M, Rodríguez-Gutiérrez R, Tamez-Pérez H, González-González J (2014) Acute pancreatitis and diabetic ketoacidosis following L-Asparaginase/prednisone therapy in acute lymphoblastic leukemia. Case Rep Oncol Med 2014:1–3CrossRef
11.
Zurück zum Zitat Saha A, Salley CG, Saigal P, Rolnitzky L, Goldberg J, Scott S, etal (2014) Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols. Pediat Blood Cancer 61(9):1644--1672 Saha A, Salley CG, Saigal P, Rolnitzky L, Goldberg J, Scott S, etal (2014) Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols. Pediat Blood Cancer 61(9):1644--1672
12.
Zurück zum Zitat Green DM, Sklar CA, Boice JD, Mulvihill JJ, Whitton JA, Stovall M, Yasui Y (2009) Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 27(14):2374-2381 Green DM, Sklar CA, Boice JD, Mulvihill JJ, Whitton JA, Stovall M, Yasui Y (2009) Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 27(14):2374-2381
13.
Zurück zum Zitat Ginsberg JP (2011) New advances in fertility preservation for pediatric cancer patients. Curr Opin Pediatr 23(1): 9 Ginsberg JP (2011) New advances in fertility preservation for pediatric cancer patients. Curr Opin Pediatr 23(1): 9
14.
Zurück zum Zitat Çağlar AA, Oğuz A, Pınarlı FG, Karadeniz C, Okur A, Bideci A, et al (2014) Thyroid abnormalities in survivors of childhood cancer. J Clin Res Pediat Endocrinol 6(3):144 Çağlar AA, Oğuz A, Pınarlı FG, Karadeniz C, Okur A, Bideci A, et al (2014) Thyroid abnormalities in survivors of childhood cancer. J Clin Res Pediat Endocrinol 6(3):144
15.
Zurück zum Zitat Lee HJ, Hahn SM, Jin SL, Shin YJ, Kim SH, Lee YS, et al (2016) Subclinical Hypothyroidism in Childhood Cancer Survivors. Yonsei Med J 57(4):915--922 Lee HJ, Hahn SM, Jin SL, Shin YJ, Kim SH, Lee YS, et al (2016) Subclinical Hypothyroidism in Childhood Cancer Survivors. Yonsei Med J 57(4):915--922
16.
Zurück zum Zitat Chow EJ, Pihoker C, Hunt K, Wilkinson K, Friedman DL (2007) Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 110:2313–2320CrossRefPubMed Chow EJ, Pihoker C, Hunt K, Wilkinson K, Friedman DL (2007) Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 110:2313–2320CrossRefPubMed
17.
Zurück zum Zitat Tonorezos E, Vega G, Sklar C, Chou J, Moskowitz C, Mo Q, Church T et al (2012) Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia. Pediatr Blood Cancer 58(1):31–36CrossRefPubMed Tonorezos E, Vega G, Sklar C, Chou J, Moskowitz C, Mo Q, Church T et al (2012) Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia. Pediatr Blood Cancer 58(1):31–36CrossRefPubMed
18.
Zurück zum Zitat Van Waas M, Neggers S, Raat H, Rij C, Pieters R, Heuvel-Eibrink M (2012) Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors. PLoS One 7(12), e52237CrossRefPubMedPubMedCentral Van Waas M, Neggers S, Raat H, Rij C, Pieters R, Heuvel-Eibrink M (2012) Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors. PLoS One 7(12), e52237CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Chemaitilly W, Sklar CA (2010) Endocrine complications in long-term survivors of childhood cancers. Endocr-Relat Cancer 17(3):R141–R159CrossRefPubMed Chemaitilly W, Sklar CA (2010) Endocrine complications in long-term survivors of childhood cancers. Endocr-Relat Cancer 17(3):R141–R159CrossRefPubMed
20.
Zurück zum Zitat Scott JX, Latha MS, Aruna R (2015) Approach to metabolic syndrome in childhood cancer survivors. Indian J Cancer 52(2):169CrossRefPubMed Scott JX, Latha MS, Aruna R (2015) Approach to metabolic syndrome in childhood cancer survivors. Indian J Cancer 52(2):169CrossRefPubMed
21.
Zurück zum Zitat Prasad M, Arora B, Chinnaswamy G, Vora T, Narula G, Banavali, S, Kurkure P (2015) Nutritional status in survivors of childhood cancer: Experience from Tata Memorial Hospital, Mumbai. Indian J Cancer 52(2):219 Prasad M, Arora B, Chinnaswamy G, Vora T, Narula G, Banavali, S, Kurkure P (2015) Nutritional status in survivors of childhood cancer: Experience from Tata Memorial Hospital, Mumbai. Indian J Cancer 52(2):219
22.
Zurück zum Zitat Esbenshade AJ, Simmons JH, Koyama T, Lindell RB, Friedman DL (2013) Obesity and insulin resistance in pediatric acute lymphoblastic leukemia worsens during maintenance therapy. Pediatr Blood Cancer 60(8):1287–1291CrossRefPubMed Esbenshade AJ, Simmons JH, Koyama T, Lindell RB, Friedman DL (2013) Obesity and insulin resistance in pediatric acute lymphoblastic leukemia worsens during maintenance therapy. Pediatr Blood Cancer 60(8):1287–1291CrossRefPubMed
23.
Zurück zum Zitat Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R (2005) Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol /Eur Fed Endocr Soc 153(1):81–89CrossRef Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R (2005) Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol /Eur Fed Endocr Soc 153(1):81–89CrossRef
24.
Zurück zum Zitat Smith W, Li C, Nottage K, Mulrooney D, Armstrong G, Lanctot J, Chemaitilly W et al (2014) Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer 120(17):2742–2750CrossRefPubMedPubMedCentral Smith W, Li C, Nottage K, Mulrooney D, Armstrong G, Lanctot J, Chemaitilly W et al (2014) Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer 120(17):2742–2750CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Song Y, Li TY, van Dam RM, Manson JE, Hu FB (2007) Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr 85(4):1068–1074PubMed Song Y, Li TY, van Dam RM, Manson JE, Hu FB (2007) Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr 85(4):1068–1074PubMed
27.
Zurück zum Zitat Yeung SCJ, Chiu AC, Vassilopoulou-Sellin R, Gagel RF (1998) The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 19(2):144–172CrossRefPubMed Yeung SCJ, Chiu AC, Vassilopoulou-Sellin R, Gagel RF (1998) The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 19(2):144–172CrossRefPubMed
28.
Zurück zum Zitat Marseglia L, Manti S, D’Angelo G, Nicotera A, Parisi E, Di Rosa G et al (2014) Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci 16(1):378–400CrossRefPubMedPubMedCentral Marseglia L, Manti S, D’Angelo G, Nicotera A, Parisi E, Di Rosa G et al (2014) Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci 16(1):378–400CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Rafacho A, Ortsäter H, Nadal A, Quesada I (2014) Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. J Endocrinol 223(3):R49–R62CrossRefPubMed Rafacho A, Ortsäter H, Nadal A, Quesada I (2014) Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. J Endocrinol 223(3):R49–R62CrossRefPubMed
30.
Zurück zum Zitat Cha JY, Kim HJ, Yu JH, Xu J, Kim D, Paul BD et al (2013) Dexras1 mediates glucocorticoid-associated adipogenesis and diet-induced obesity. Proc Natl Acad Sci 110(51):20575–20580CrossRefPubMedPubMedCentral Cha JY, Kim HJ, Yu JH, Xu J, Kim D, Paul BD et al (2013) Dexras1 mediates glucocorticoid-associated adipogenesis and diet-induced obesity. Proc Natl Acad Sci 110(51):20575–20580CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Veyrat-Durebex C, Deblon N, Caillon A, Andrew R, Altirriba J, Odermatt A, Rohner-Jeanrenaud F (2012) Central glucocorticoid administration promotes weight gain and increased 11β-hydroxysteroid dehydrogenase type 1 expression in white adipose tissue. PLoS One 7(3), e34002CrossRefPubMedPubMedCentral Veyrat-Durebex C, Deblon N, Caillon A, Andrew R, Altirriba J, Odermatt A, Rohner-Jeanrenaud F (2012) Central glucocorticoid administration promotes weight gain and increased 11β-hydroxysteroid dehydrogenase type 1 expression in white adipose tissue. PLoS One 7(3), e34002CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat James EL, Stacey FG, Chapman K, Boyes AW, Burrows T, Girgis et al (2015) Impact of a nutrition and physical activity intervention (ENRICH: Exercise and Nutrition Routine Improving Cancer Health) on health behaviors of cancer survivors and carers: a pragmatic randomized controlled trial. BMC Cancer 15(1):1CrossRef James EL, Stacey FG, Chapman K, Boyes AW, Burrows T, Girgis et al (2015) Impact of a nutrition and physical activity intervention (ENRICH: Exercise and Nutrition Routine Improving Cancer Health) on health behaviors of cancer survivors and carers: a pragmatic randomized controlled trial. BMC Cancer 15(1):1CrossRef
33.
Zurück zum Zitat Liang Y, Tan A, Liang D, Yang X, Liao M, Gao Y, Jiang Y et al (2015) Low osteocalcin level is a risk factor for impaired glucose metabolism in a Chinese male population. J Diabetes Inv 7(4):522–528CrossRef Liang Y, Tan A, Liang D, Yang X, Liao M, Gao Y, Jiang Y et al (2015) Low osteocalcin level is a risk factor for impaired glucose metabolism in a Chinese male population. J Diabetes Inv 7(4):522–528CrossRef
34.
Zurück zum Zitat Haugnes H, Aass N, Fosså S, Dahl O, Klepp O, Wist E, Svartberg J et al (2007) Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18(2):241–248CrossRefPubMed Haugnes H, Aass N, Fosså S, Dahl O, Klepp O, Wist E, Svartberg J et al (2007) Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18(2):241–248CrossRefPubMed
35.
Zurück zum Zitat Ebrahimi F, Christ-Crain M (2016) Metabolic syndrome and hypogonadism—two peas in a pod. Swiss Med Wkly 146 Ebrahimi F, Christ-Crain M (2016) Metabolic syndrome and hypogonadism—two peas in a pod. Swiss Med Wkly 146
36.
Zurück zum Zitat Chow E, Pihoker C, Friedman D, Lee S, McCune J, Wharton C, Roth C et al (2013) Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 60(4):621–626CrossRefPubMed Chow E, Pihoker C, Friedman D, Lee S, McCune J, Wharton C, Roth C et al (2013) Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 60(4):621–626CrossRefPubMed
37.
Zurück zum Zitat Waas M, Neggers S, Eck J, Noesel M, Lely A-J, Jong F, Pieters R et al (2012) Adrenal function in adult long-term survivors of nephroblastoma and neuroblastoma. Eur J Cancer 48(8):1159–1166CrossRefPubMed Waas M, Neggers S, Eck J, Noesel M, Lely A-J, Jong F, Pieters R et al (2012) Adrenal function in adult long-term survivors of nephroblastoma and neuroblastoma. Eur J Cancer 48(8):1159–1166CrossRefPubMed
38.
Zurück zum Zitat Ferrau F, Korbonits M (2015) Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 173(4):M133–M157CrossRefPubMed Ferrau F, Korbonits M (2015) Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 173(4):M133–M157CrossRefPubMed
39.
Zurück zum Zitat Chemaitilly W, Li Z, Huang S, Ness K, Clark K, Green D, Barnes N et al (2015) Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude lifetime cohort study. J Clin Oncol 33(5):492–500CrossRefPubMedPubMedCentral Chemaitilly W, Li Z, Huang S, Ness K, Clark K, Green D, Barnes N et al (2015) Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude lifetime cohort study. J Clin Oncol 33(5):492–500CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Pradhan K, Mund J, Case J, Gupta S, Liu Z, Gathirua-Mwangi W, McDaniel A et al (2015) Differences in circulating endothelial progenitor cells among childhood cancer survivors treated with and without radiation. J Hematol Thromb 1(1) Pradhan K, Mund J, Case J, Gupta S, Liu Z, Gathirua-Mwangi W, McDaniel A et al (2015) Differences in circulating endothelial progenitor cells among childhood cancer survivors treated with and without radiation. J Hematol Thromb 1(1)
41.
Zurück zum Zitat Valcovici M, Andrica F, Serban C, Dragan S (2016) Cardiotoxicity of anthracycline therapy: current perspectives. Arch Med Sci 2:428–435CrossRef Valcovici M, Andrica F, Serban C, Dragan S (2016) Cardiotoxicity of anthracycline therapy: current perspectives. Arch Med Sci 2:428–435CrossRef
42.
Zurück zum Zitat Geisberg C, Sawyer DB (2010) Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep 12(6):404–410CrossRefPubMedPubMedCentral Geisberg C, Sawyer DB (2010) Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep 12(6):404–410CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Kucharz J, Michalowska-Kaczmarczyk A, Zygulska AL, Wojtak J, Pawlik W, Herman RM, Krzemieniecki K (2016) Bradycardia as a rare symptom of cisplatin cardiotoxicity: a case report. Oncol Lett 11(3):2297–2299PubMedPubMedCentral Kucharz J, Michalowska-Kaczmarczyk A, Zygulska AL, Wojtak J, Pawlik W, Herman RM, Krzemieniecki K (2016) Bradycardia as a rare symptom of cisplatin cardiotoxicity: a case report. Oncol Lett 11(3):2297–2299PubMedPubMedCentral
44.
Zurück zum Zitat Altena R, Fehrmann RSN, Boer H, de Vries EGE, Meijer C, Gietema JA (2015) Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage. PLoS ONE 10(1), e0115372CrossRefPubMedPubMedCentral Altena R, Fehrmann RSN, Boer H, de Vries EGE, Meijer C, Gietema JA (2015) Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage. PLoS ONE 10(1), e0115372CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Nuver J, Smit AJ, Sleijfer DT, Van Gessel AI, Van Roon AM, Van der Meer J et al (2004) Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 40(5):701–706CrossRefPubMed Nuver J, Smit AJ, Sleijfer DT, Van Gessel AI, Van Roon AM, Van der Meer J et al (2004) Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 40(5):701–706CrossRefPubMed
46.
Zurück zum Zitat Dostálová I, Roubíček T, Bártlová M, Mráz M, Lacinová Z, Haluzíková D et al (2009) Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 161(3):397–404CrossRefPubMed Dostálová I, Roubíček T, Bártlová M, Mráz M, Lacinová Z, Haluzíková D et al (2009) Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet. Eur J Endocrinol 161(3):397–404CrossRefPubMed
47.
Zurück zum Zitat Hellemons ME, Mazagova M, Gansevoort RT, Henning RH, de Zeeuw D, Bakker SJL, Deelman LE (2012) Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care 35(11):2340–2346CrossRefPubMedPubMedCentral Hellemons ME, Mazagova M, Gansevoort RT, Henning RH, de Zeeuw D, Bakker SJL, Deelman LE (2012) Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care 35(11):2340–2346CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat De Baaij JH, Hoenderop JG, Bindels RJ (2015) Magnesium in man: implications for health and disease. Physiol Rev 95(1):1–46CrossRefPubMed De Baaij JH, Hoenderop JG, Bindels RJ (2015) Magnesium in man: implications for health and disease. Physiol Rev 95(1):1–46CrossRefPubMed
49.
Zurück zum Zitat Yang H-Q, Qiu F-Q, Jin K, Jiang N-G, Zhang L (2015) High plasma levels of oxidatively modified low-density lipoproteins are associated with the suppressed expression of immunomodulatory molecules in patients with hematological malignancies. Exp Ther Med 9(6):2394–2400PubMedPubMedCentral Yang H-Q, Qiu F-Q, Jin K, Jiang N-G, Zhang L (2015) High plasma levels of oxidatively modified low-density lipoproteins are associated with the suppressed expression of immunomodulatory molecules in patients with hematological malignancies. Exp Ther Med 9(6):2394–2400PubMedPubMedCentral
50.
Zurück zum Zitat Galindo RJ, Yoon J, Devoe C, Myers AK (2015) PEG-asparaginase induced severe hypertriglyceridemia. Arch Endocrinol Metab 60(2):173–177CrossRefPubMed Galindo RJ, Yoon J, Devoe C, Myers AK (2015) PEG-asparaginase induced severe hypertriglyceridemia. Arch Endocrinol Metab 60(2):173–177CrossRefPubMed
Metadaten
Titel
Development of Metabolic Syndrome Associated to Cancer Therapy: Review
verfasst von
Stephania Casco
Elena Soto-Vega
Publikationsdatum
04.10.2016
Verlag
Springer US
Erschienen in
Discover Oncology / Ausgabe 5-6/2016
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-016-0274-1

Weitere Artikel der Ausgabe 5-6/2016

Discover Oncology 5-6/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.